Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Josef Svejk who wrote (1577)	3/26/1998 5:15:00 PM
From: M. Frank Greiffenstein	Read Replies (3) \| Respond to of 5736

Josef, It turns out that the partner of my daughter's pediatrician is on staff at both Providence and Beaumont hospitals. He knows all the peeds people at Beaumont. He is not a part of the study, but he knows of it and is familiar with the protocol. He is impressed with the Colormate, and tells me that the neonatal specialists that he knows are happy with it. He couldn't give me exact figures on sensitivity and specificity of the device because he doens't know, nor would he tell me if he did know. But the bottom line is that if the diagnostic hit rates are comparable to that of heelpricks, Colormate is the superior choice because of the absence of side effects, because of the convenience, and because of lower labor costs. How does this translate into investment decisions? It seems to me that what I was told is not startling. I doubt CCSI would plan a big rollout out of the product before knowing the results. That would be suicidal, LOL. But rest assurred that Maisels is a very respected doctor in Southeastern Michigan, he does not associate himself with scamsters and opportunists. He has a publication list a mile long. Take care, DocStone (the "other" Manfred <g>)